
Solid Biosciences (SLDB) Stock Forecast & Price Target
Solid Biosciences (SLDB) Analyst Ratings
Bulls say
Solid Biosciences is well positioned to become a leader in the treatment of neuromuscular and cardiac diseases, with a strong pipeline and promising treatment candidates. With enough financial resources to support operations and upcoming trial milestones, the company has the potential to significantly improve the lives of patients with genetic diseases.
Bears say
Solid Biosciences is currently facing a number of challenges that could negatively impact the company's future growth prospects. These include the need for additional funding for the development of their gene therapy treatments, potential delays or increased requirements from regulatory agencies, and uncertainty surrounding the relationship between their surrogate marker and potential clinical benefits. While the company remains a top pick for a longer time horizon, the current FDA turmoil and general market conditions may lead to a shift in their target price, currently at $16. The recent resignation of FDA commissioner Marty Makary is not expected to impact the company's ongoing interactions with the agency, but data releases may be delayed as the company focuses on preserving data for discussions with FDA. Additionally, the company's recent dosing of SGT-212 in Friedreich's ataxia and expected data release by the end of 2026, as well as the upcoming dosing of SGT-501 in CPVT in 2H26, may provide some positive momentum, but it remains to be seen how these treatments will perform in clinical trials. The company's cash runway into 1H28 may provide some stability, but further funding will be needed for their pipeline programs. Overall, the company's current challenges and uncertainties make us believe that a negative outlook is warranted for their stock.
This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Solid Biosciences (SLDB) Analyst Forecast & Price Prediction
Start investing in Solid Biosciences (SLDB)
Order type
Buy in
Order amount
Est. shares
0 shares